China Pharma Holdings Inc (CPHI)vsHaleon plc (HLN)
CPHI
China Pharma Holdings Inc
$0.59
-6.19%
HEALTHCARE · Cap: $4.96M
HLN
Haleon plc
$9.74
+0.41%
HEALTHCARE · Cap: $44.83B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 250799% more annual revenue ($11.03B vs $4.40M). HLN leads profitability with a 15.1% profit margin vs -83.2%. CPHI appears more attractively valued with a PEG of 0.16. HLN earns a higher WallStSmart Score of 58/100 (C).
CPHI
Hold47
out of 100
Grade: D+
HLN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CPHI.
Margin of Safety
+51.3%
Fair Value
$22.93
Current Price
$9.74
$13.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 92.0% YoY
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -52.7% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
0.6% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : CPHI
The strongest argument for CPHI centers on PEG Ratio, Price/Book. Revenue growth of 10.9% demonstrates continued momentum. PEG of 0.16 suggests the stock is reasonably priced for its growth.
Bull Case : HLN
The strongest argument for HLN centers on EPS Growth, Operating Margin, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bear Case : CPHI
The primary concerns for CPHI are EPS Growth, Market Cap, Return on Equity.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
CPHI profiles as a turnaround stock while HLN is a value play — different risk/reward profiles.
CPHI carries more volatility with a beta of 1.04 — expect wider price swings.
CPHI is growing revenue faster at 10.9% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (58/100 vs 47/100), backed by strong 15.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
China Pharma Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · China
China Pharma Holdings, Inc. develops, manufactures and markets generic and branded pharmaceutical and biochemical products primarily for hospitals and private retailers in the People's Republic of China. The company is headquartered in Haikou, the People's Republic of China.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?